David Ebb

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

David Ebb, Paul A. Meyers, Holcombe E. Grier et al. · Journal of Clinical Oncology · 2012 · 250 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.

Susan Chi, Franck Bourdeaut, Theodore W. Laetsch et al. · Journal of Clinical Oncology · 2020 · 33 citations

Medicine, Oncology, Pharmacology +16

Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy

Sujith Baliga, Sara L. Gallotto, B. Bajaj et al. · Neuro-Oncology · 2021 · 20 citations · Full text

Medicine, Oncology, Surgery +17

CTNI-53. PNOC014: PHASE IB STUDY RESULTS OF DAY101(TOVORAFENIB) FOR CHILDREN WITH LOW-GRADE GLIOMAS (LGGS) AND OTHER RAS/RAF/MEK/ERK PATHWAY-ACTIVATED TUMORS

Karen Wright, Cassie Kline, Mohamed S Abdelbaki et al. · Neuro-Oncology · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17

Results from a Prospective Trial of Proton Radiotherapy for Medulloblastoma: Clinical Outcomes including Hearing and Neurocognitive

Torunn I. Yock, B.Y. Yeap, David Ebb et al. · International Journal of Radiation Oncology*Biology*Physics · 2011 · 10 citations

Medicine, Oncology, Radiation Oncology +16